Gene therapy biotech whose lead product Vyjuvek is a topical redosable gene therapy for a rare, blistering skin disease.
Gene therapy biotech whose lead product Vyjuvek is a topical redosable gene therapy for a rare, blistering skin disease.
Almost all revenue comes from one product, Vyjuvek, a gel applied at home that insurers pay for as a high-priced rare-disease medicine, with patients served through a central support and distribution process. US approval came in 2023, and approvals outside the US followed in 2025. Other gene therapies, including for lung disease, are still in development.
Moat: narrow (IP / patents, regulatory licence). The first and only approved redosable topical gene therapy, on a patent-protected HSV-1 delivery vector platform.
Headquarters: Pittsburgh, Pennsylvania, US · Founded: 2016 · Employees: 295
Size Krystal Biotech (KRYS) is a United States Health Care company (Biotechnology) with a market value of $9.34B, the 808th largest of 3,085 United States companies the cockpit tracks. Shares closed at $315.34 on 18 Nov 2026.
Performance Over six months the shares gained 4.4%, against +23.8% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 26.0% over the last twelve months (peer median +25.2%); the operating margin is 48.4% (peer median -1.9%).
Valuation It trades at 36.3× forward earnings against a peer median of 34.4× (4th most expensive of 10).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +26%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 25.9 points above its cost of capital (7.9% WACC).
Short interest Short interest is 10.3% of the free float (30 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $470M | $389M | $291M | $50.7M | $0 |
| Revenue growth | — | +34% | +473% | — | — |
| Gross profit | $437M | $360M | $264M | $42.6M | -$4.05M |
| EBITDA | $234M | $168M | $110M | -$92.2M | -$116M |
| Net income | $225M | $205M | $89.2M | $10.9M | -$140M |
| Free cash flow | $310M | $189M | $119M | -$101M | -$154M |
| Capital expenditure | $13.8M | $12.0M | $4.24M | $11.8M | $53.0M |
| Total debt | $8.59M | $9.34M | $7.26M | $8.09M | $8.93M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Krystal Biotech KRYS | $9.34B | +4% | +26% | 48% | 36.3× | 13.1% |
| Abeona Therapeutics ABEO | n/a | -49% | n/a | n/a | n/a | n/a |
| Ionis Pharmaceuticals IONS | $4.56B | -64% | -1% | -59% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | KRYS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.1% | -4.9% | 11th highest of 21 |
| 6-month return | +4.4% | +23.8% | 7th lowest of 21 |
| Distance from 52-week high | -17.6% | -26.2% | 8th highest of 21 |
| Revenue growth (TTM) | +26.0% | +25.2% | 8th highest of 16 |
| Operating margin | 48.4% | -1.9% | 3rd highest of 17 |
| Forward P/E | 36.3× | 34.4× | 4th most expensive of 10 |
| Growth the price implies (Req g, 7 yrs) | 13.1% | 24.6% | 5th least demanding of 10 |
| Growth delivered (Del g) | +26.0% | +12.0% | 3rd highest of 10 |
| Hurdle (Req g minus delivered) | -12.8 pp | +3.8 pp | 3rd least demanding of 10 |
| ROIC minus cost of capital | +25.9 pp | -5.7 pp | 3rd highest of 14 |
| EV / EBITDA | 36.0× | 15.8× | 3rd most expensive of 8 |
| Net debt / EBITDA | -3.9× | -0.2× | least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Krystal Biotech KRYS | United States | $9.34B | +4% | +26% | 48% | 36.3× | 13.1% | +26.0% |
| Vaxcyte PCVX | United States | $9.26B | +24% | n/a | n/a | n/a | n/a | n/a |
| ALTEOGEN 196170.KS | South Korea | $8.80B | -56% | +61% | 53% | 42.0× | 24.6% | +38.5% |
| Genscript Biotech 1548.HK | Hong Kong | $8.69B | +133% | +53% | 12% | 294.1× | 36.9% | +19.8% |
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.1B | +35% | 0% | 9% | 35.6× | 6.2% | +2.3% |
| Kymera Therapeutics KYMR | United States | $10.3B | +50% | +134% | -396% | n/a | n/a | n/a |
| Summit Therapeutics SMMT | United States | $8.40B | -41% | n/a | n/a | n/a | n/a | n/a |
| Halozyme Therapeutics HALO | United States | $10.9B | +39% | +45% | 57% | 9.5× | -0.3% | +39.2% |
| Twist Bioscience TWST | United States | $7.93B | +117% | +22% | -29% | n/a | n/a | n/a |
| Bio-Techne TECH | United States | $11.4B | +56% | +1% | 21% | 34.4× | 31.6% | +5.5% |
| 10x Genomics TXG | United States | $7.51B | +138% | -4% | -11% | n/a | 47.2% | +16.6% |
| BioMarin Pharmaceutical BMRN | United States | $11.9B | +22% | +20% | 19% | 11.2× | 8.2% | +12.0% |
| Cspc Pharma 1093.HK | Hong Kong | $12.0B | +10% | +25% | 28% | 9.1× | -10.7% | +0.1% |
| CG Oncology CGON | United States | $7.15B | +24% | +184% | -4,294% | n/a | n/a | n/a |
| Axsome Therapeutics AXSM | United States | $7.05B | -42% | +54% | -19% | 77.1× | n/a | n/a |
| Immunovant IMVT | United States | $6.86B | -7% | n/a | n/a | n/a | n/a | n/a |
| Elanco Animal Health ELAN | United States | $13.3B | +28% | +12% | 8% | 21.5× | 32.9% | +7.6% |
| Kodiak Sciences KOD | United States | $6.40B | +170% | n/a | n/a | n/a | n/a | n/a |
| Arrowhead Pharmaceuticals ARWR | United States | $6.09B | -44% | -46% | -157% | n/a | n/a | n/a |
| Scholar Rock SRRK | United States | $5.86B | -1% | n/a | -71,732% | n/a | n/a | n/a |
| BridgeBio Pharma BBIO | United States | $15.2B | +14% | +167% | -37% | n/a | n/a | n/a |